Zhejiang Anglikang Pharmaceutical Co Ltd

Zhejiang Anglikang Pharmaceutical Co Ltd maintains a relatively balanced capital structure, with a debt-to-equity ratio of 0.38, indicating a moderate reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 2.01, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company's net cash position is negative after subtracting total debt, which raises concerns about its ability to meet long-term obligations without additional financing.

In terms of profitability, the company's return on equity (ROE) is 2.49%, and its return on assets (ROA) is 1.27%. These figures are below the typical thresholds for strong performance in the pharmaceutical industry, where ROE and ROA are often higher due to the sector's capital intensity and high-margin product offerings. The company's net income of CNY 39.88 million is modest relative to its total assets of CNY 3.15 billion, indicating that it is not generating strong returns on its asset base.

The company's revenue is concentrated in a single geographic market, China, and it does not disclose segment-level revenue data. This lack of diversification increases its exposure to domestic economic and regulatory risks. The absence of international revenue or segment breakdowns limits the ability to assess the company's strategic positioning or growth potential beyond its home market.

Looking ahead, the company's growth trajectory is uncertain. While it has a positive operating cash flow of CNY 195.6 million, its capital expenditures are negative at CNY -62.24 million, suggesting a reduction in investment in new projects or facilities. This could indicate a conservative approach to growth or a focus on cost control. The company's revenue outlook for the current fiscal year is not explicitly provided, but the lack of significant capital spending may signal a pause in expansion.

The company faces several risk factors, including its medium liquidity risk and the potential for dilution, although the risk of dilution is currently assessed as low. The negative net cash position after subtracting total debt is a red flag, as it suggests the company may need to raise additional capital in the near term to fund operations or debt obligations. The absence of a clear dilution strategy or recent equity issuance makes it difficult to assess the likelihood or timing of such an event.

Recent events and disclosures do not provide a clear picture of the company's strategic direction or financial health. The company has not filed any notable recent reports or transcripts that would shed light on its operational performance or future plans. This lack of transparency may make it challenging for investors to make informed decisions about the company's long-term prospects.

Zhejiang Anglikang Pharmaceutical Co Ltd (002940.SZ) has been formally classified within the Healthcare economic sector, with its primary activity identified as Pharmaceuticals. This taxonomic update provides a clearer structural definition of the company’s operational focus, aligning its profile with industry standards for sector-based analysis. Concurrently, the company’s risk assessment framework has been initialized with specific metrics. Dilution risk is now rated as low, indicating a stable capital structure with minimal threat of share value erosion from new issuances. This assessment offers investors a baseline for evaluating the security of their equity position against potential dilution events. Liquidity risk, however, is assessed at a medium level. This classification suggests that while the company maintains operational viability, there may be moderate constraints or volatility in its ability to meet short-term financial obligations or trade volume expectations. This distinction is critical for understanding the balance between capital stability and cash flow dynamics. The company currently operates with a lean executive structure, reporting only one officer, and lacks coverage from financial analysts or inclusion in major market indices. With no top holders identified, the stock appears to have limited institutional visibility, making these newly established risk and sector classifications particularly significant for independent investors seeking to understand the fundamental profile of Zhejiang Anglikang. [doc:002940.sz-ha-financials]

Cash conversion ratio of 4.9 is best-in-class compared to the cohort median of 0.95, showing strong efficiency.

Net income surged 56.1% year-over-year to CNY 125.4 million, demonstrating significant recent earnings growth.

Free cash flow increased 46.9% to CNY 125.4 million, providing robust liquidity for future investments.

The company faces high credit risk, which could impair financial stability and increase borrowing costs.

Medium liquidity risk suggests potential challenges in meeting short-term financial obligations promptly.

Four-year revenue CAGR of only 0.8% indicates stagnant long-term growth compared to industry expansion.

Revenue ¥1.38B; Operating income ¥173.6M.

• ▍Revenue ¥1.38B
• ▍Operating income ¥173.6M
• ▍Net margin 8.7%